HUE027731T2 - Új európai PRRSV-törzs - Google Patents

Új európai PRRSV-törzs Download PDF

Info

Publication number
HUE027731T2
HUE027731T2 HUE12704409A HUE12704409A HUE027731T2 HU E027731 T2 HUE027731 T2 HU E027731T2 HU E12704409 A HUE12704409 A HU E12704409A HU E12704409 A HUE12704409 A HU E12704409A HU E027731 T2 HUE027731 T2 HU E027731T2
Authority
HU
Hungary
Prior art keywords
prrs
challenge
group
vaccine
prrsv
Prior art date
Application number
HUE12704409A
Other languages
English (en)
Inventor
Kim Burgard
Jeremy Kroll
Sarah M Layton
Volker Ohlinger
Francois-Xavier Orveillon
Stefan Pesch
Michael Dennis Piontkowski
Michael B Roof
Philip Utley
Eric Martin Vaughn
Original Assignee
Boehringer Ingelheim Vetmedica Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Vetmedica Gmbh filed Critical Boehringer Ingelheim Vetmedica Gmbh
Publication of HUE027731T2 publication Critical patent/HUE027731T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/10011—Arteriviridae
    • C12N2770/10021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/10011—Arteriviridae
    • C12N2770/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/10011—Arteriviridae
    • C12N2770/10061—Methods of inactivation or attenuation
    • C12N2770/10064—Methods of inactivation or attenuation by serial passage
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/10011—Arteriviridae
    • C12N2770/10071—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Claims (12)

  1. m Z $73 Clj earéjmí PRRSV-törzs igénypontok ;î, Európai típusn sériés reprodrÉÂs és légzésiem szindróma vírus ψΜRSV), amely az Európai Sejitenyészet Gyűjteményben (ECACC) ECACG 11012501 nyilvántartási szánon letétbe helyezett törzs,
  2. 2, Európai fíptisu Sértés reprodtifíéiós és légzőszervi szindróma vims (PRRSV), amely az Európai Ssjttenyészet Gyűjtemény bee |B€ACC) EÇAÇÇ 11012502 számon tóétbe helyezett törzs, J, A 2. igénypont szerinti PRRSV, amely setttényészetben Só-szoros passzálással oly módon leit legyengítve, melynek eredményeként i módi®sított vírus sertésbe vagy egyéb, PRRSY-re fogékony emlősbe történd bejuttatást követően nem képes a PRRSV betegség klinikai tünetéit kiváltani, azonban képes olyan immunreakeiot indukálni, amely az emlőst im-Manlzl|a a PRRSV patogéa alakjaival szemben,
  3. 4, Eljárás a 2, igénypont szerinti élő,legyengíteti PRRSV előállítására, mely eljárás magában foglalja égy 1, igénypont szerinti, 'MÄ 104-en növesztett európai típusú PRRSV nem MA 104 emlős sejtekhez történő adaptálását, S; Vakcina sertések FERSY-fertőzéssei szembeni védettségének kialakítására, mely vak-eina 2, igénypont szerinti élő, legyengített PRRSY-t és győgyászatilag elfogadható hordozót tartalmaz,
  4. 6. Az 5, igénypont szerinti vakcina, amely tartalmaz mvabbá egy vagy több legpngííett vagy ínakílvált nem*FRRSV patogént vagy annak antigén hatási anyagát. f, A. Ói. igénypont szerinti vakcina, ahol a nem-PRRSV patogének a következők közül vannak kiválasztva: Pseudorabies vírus, sértési nil uenza vírus, sertés parvovirus, transzmisszibiiis gastroenteritis vims, Escherichia coli, Erysipelo rhusiopatbiae, Bordetella bronehiseptica, Salmonella oholeraesuiSi, Haemophilus pamsuis, Pastenmlla moltoeida, Streptococcus suis. Mycoplasma hyopneumomae és Aeimohaciiius pleuropneumoniae.
    5, Az 5, igénypont szerinti vakcina, amely tartalmaz még a következőkből álló csoportból kiválasztott egy vagy több további európai PRESV-torzset Is: Eelystad vírwtöfzs (Lelystad jugent (CDI-NL-2.9I), valamint m alábbi nyilvántartási számokon letétbe helyeseit egyéb törzsek: iCAÜC 04102703, ECACC 04102702, ECACC 04102704, CNCM Mo, I-Ü40, CNCM :1.1:387, CNCM 1-1388, ATCC VR 2332, VR 2385, VR 2386, YR 2429, VR 2474, és VR 2402; CNCM 1-1102:, CNCM: 1-114¾ CNCM 1-1387, CNCM 1-1388, vagy ECACC V9307Ö108; vagy egy egyesült államokbeli törzset, pl. észak-amerikai PRRS-virust pT7P129A; ATCC VR-2332, ATCC VR-2368; ATCC VR-2495; ATCC VR 2385, ATCC VR 2310* ATCC VR 2429, ATCC VR 2474, és ATCC VR 2402.
  5. 9. Az 5. igénypont szerinti vakcina, amely tartalmaz egy intradermális vagy mtramuszku-láris adagolásra alkalmas hordozót.
  6. 10. Az 5. igénypont szerinti vakcina, amely fagyasztva szárított.
  7. 11. Az 5. igénypont szerinti vakcina, amely legalább 10' vimsrészecskét íartaitnáz,
  8. 12. Eljárás PRRS leküzdésére alkalmas élő, legyengített vakcina előállításán, Mely éljá-fás magában foglalja egy 2. igénypont szerinti élő, legyengített PRRSV gyógyászaítlag elfogadható hordozóval történő összekeverésék 13. A 12, igénypont szerinti ei|árá% áhöl az élő, legyengített PRRS V tartalmaz egy vagy több további európai PRRSV-iörzsei is, amely (ek) a kővetkező nyilvántartási számokon letétbe helyezett PRRSV-törzsekből álló csoportból van(nák) kiválasztva: ECACC §4102703, ECACC 04102702, ECACC 04102704, CNCM 1-1140, CNCM 1-138? és CNCM 1-1388. 14. A 12. igénypont szerinti eljárás, áltól az élő, legyengíteti PRRSV tartalmaz továbbá egy adjuvánst,
  9. 15. Az 5-11. Igénypontok bármelyike szerinti vakcina sertés sertések mpoőukeiós és iégzőszervi szindrómája (PRRS) elleni immunizálására történő alkalmazásra.
  10. 16. Vakcina a 15. igénypont szerinti alkalmazásra, ahol az említeti sertés a vakeinálást követően nem mutat tüdőd változásokat.
  11. 17-PRRS-víms, amelynek nokleofidszökvenciája legalább 95 %-ban homológ az 1. vagy 10. azonosítószámú szekvenciaként (SEQ 1D NO:l vagy SEQ ID NO: 10) bemutatótt szekvenciával 18, A 17. igénypont szerinti PRRS-vírns, amely az 1. vagy 10. azónösioszamú szekvenciaként (SEQ ! D NO: 1 vagy SEQ ID NO: 10) bemutatóit brr.
  12. 19, Vakcina sertések PRRSVkfeziözésse! szembeni védettségének kialakítására, amely vakcina tartalmaz egy 17. vagy 18. igény pent szerinti PRRS-vírasi és egy gyögyaszaíilag él-fogadható hordozót, ahol az említett PRRS-vírus az 1. azonosítószámú szekvenciaként (SEQ 1D NO:l) bemutatott nukIeotidszekvenciával hír, vagy amely egy legyengíteti PRRS-vírus, amelynek nukleoíMs^^ 95 %-ban homológ az 1, azososífoszátnü szekven ciaként (SEQ 1D NO; 1) bemutatott nukleotklszckvenclával. 20, A 19. igénypont szertníí vakcina, amely taraimaz továbbá egy vagy több legyengíteti vagy inaktiváií nem~PERS V jsatogént vagy annak antigén hatású anyagát. 21, A 20. igénypont szerinti vakcina, ahol az említett nem-PRRSV patogenek a következők közöl vannak kiválasztva:: Pseudomhiea virus, sétdésinfluenza vírus, sertés parvovirus, fomszmksziMis gastroenteritis vírus, Eimtaádm coli, Erysípdo fousiopaibiae, Bordetella bronchi sepíiea, Salmonella choleraesuis, Haemophilus parasuís, Pasteurelia múltoddá. Streptococcus suis, Mycoplasma hyöpneumoniae és Actinobacíllus pleuropneumoniae.
HUE12704409A 2011-02-17 2012-02-14 Új európai PRRSV-törzs HUE027731T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161444074P 2011-02-17 2011-02-17

Publications (1)

Publication Number Publication Date
HUE027731T2 true HUE027731T2 (hu) 2016-10-28

Family

ID=45614840

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE12704409A HUE027731T2 (hu) 2011-02-17 2012-02-14 Új európai PRRSV-törzs

Country Status (30)

Country Link
US (4) US8765142B2 (hu)
EP (2) EP2959916B1 (hu)
JP (1) JP5788027B2 (hu)
KR (2) KR102073075B1 (hu)
CN (2) CN103370078B (hu)
AR (2) AR085272A1 (hu)
AU (2) AU2012217169B2 (hu)
BR (2) BR122021013826B1 (hu)
CA (1) CA2826341C (hu)
CL (1) CL2013002379A1 (hu)
CO (1) CO6791570A2 (hu)
CY (1) CY1116835T1 (hu)
DK (2) DK2675475T3 (hu)
EA (2) EA038012B1 (hu)
ES (2) ES2692809T3 (hu)
HR (1) HRP20151031T1 (hu)
HU (1) HUE027731T2 (hu)
ME (1) ME02271B (hu)
MX (2) MX345188B (hu)
MY (2) MY161198A (hu)
PH (1) PH12017500962A1 (hu)
PL (2) PL2675475T3 (hu)
PT (2) PT2675475E (hu)
RS (1) RS54231B1 (hu)
SG (1) SG192820A1 (hu)
SI (1) SI2675475T1 (hu)
SM (1) SMT201500236B (hu)
TW (2) TWI665303B (hu)
UA (2) UA117272C2 (hu)
WO (1) WO2012110489A2 (hu)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA112860C2 (uk) 2011-02-17 2016-11-10 Бьорінгер Інгельхайм Ветмедіка Гмбх Спосіб одержання prrsv у комерційному масштабі
MY161198A (en) 2011-02-17 2017-04-14 Boehringer Ingelheim Vetmedica Gmbh Novel european prrsv strain
US8906385B2 (en) 2011-12-01 2014-12-09 University Of Maryland, College Park Interferon-inducing porcine reproductive and respiratory syndrome virus isolate
WO2013173443A1 (en) 2012-05-17 2013-11-21 Zoetis Llc Effective vaccination against porcine reproductive and respiratory syndrome (prrs) virus prior to weaning
US9314519B2 (en) 2012-08-21 2016-04-19 Intervet Inc. Liquid stable virus vaccines
US9457073B2 (en) * 2012-09-26 2016-10-04 University Of Manitoba Live attenuated replication-competent arteriviruses having decreased dub/deisgylating activity
US9149518B2 (en) 2012-12-07 2015-10-06 The Board Of Trustees Of The University Of Illinois Porcine reproductive and respiratory syndrome virus compositions and uses thereof
US9393298B2 (en) 2013-03-15 2016-07-19 Intervet Inc. Liquid stable bovine virus vaccines
US9480739B2 (en) 2013-03-15 2016-11-01 Intervet Inc. Bovine virus vaccines that are liquid stable
AR097762A1 (es) 2013-09-27 2016-04-13 Intervet Int Bv Formulaciones secas de vacunas que son estables a temperatura ambiente
CA2930042C (en) * 2013-12-20 2022-06-21 Boehringer Ingelheim Vetmedica Gmbh Prrs virus variant, european prrs virus cdna clone, and uses thereof
US10280199B2 (en) 2014-02-07 2019-05-07 Phibro Animal Health Corporation Coronavirus proteins and antigens
AR099470A1 (es) 2014-02-17 2016-07-27 Intervet Int Bv Vacunas de virus de aves de corral líquidas
TWI670085B (zh) * 2014-02-19 2019-09-01 荷蘭商英特威國際公司 液體穩定之豬病毒疫苗
EP3212182B1 (en) * 2014-10-27 2019-06-26 Pharmacosmos Holding A/S Treatment or prevention of anaemia in pregnant non-human mammals and offspring
CN106924726B (zh) * 2015-12-29 2021-02-09 普莱柯生物工程股份有限公司 一种用于预防猪繁殖与呼吸综合征的疫苗组合物及其制备方法和应用
EP3454893A4 (en) * 2016-05-11 2020-01-01 Phibro Animal Health Corporation COMPOSITION WITH ANTIGENS AND A MUCUTINE ADJUVAN AND METHOD FOR USE
US10279031B2 (en) 2016-05-11 2019-05-07 Phibro Animal Health Corporation Composition comprising antigens and a mucosal adjuvant and a method for using
PL3534939T3 (pl) 2016-11-03 2023-06-12 Boehringer Ingelheim Vetmedica Gmbh Szczepionka przeciw parwowirusowi świń i wirusowi zespołu rozrodczo-oddechowego świń oraz sposoby ich wytwarzania
KR102602018B1 (ko) * 2016-12-14 2023-11-15 조에티스 서비시즈 엘엘씨 젖떼기 전, 유럽의 돼지 생식기 및 호흡기 증후군 (prrs) 균주 바이러스에 대한 효과적인 백신접종
US11013796B2 (en) 2018-08-30 2021-05-25 Iowa State University Research Foundation, Inc. Porcine parainfluenza virus type 1 isolates and immunogenic compositions therefrom
US11701419B2 (en) 2019-04-04 2023-07-18 Boehringer Ingelheim Animal Health USA Inc. Porcine Circovirus Type 3 (PCV3) vaccines, and production and uses thereof
CN110735005B (zh) * 2019-11-26 2023-01-10 广西大学 Siv和prrsv多重rt-pcr快速检测试剂盒及引物
CN111676247A (zh) * 2020-06-30 2020-09-18 扬州大学 一株猪繁殖与呼吸综合征病毒1型分离株感染性克隆构建、拯救与应用
AU2021311726A1 (en) 2020-07-24 2023-02-09 Boehringer Ingelheim Animal Health USA Inc. Combination porcine vaccine
CN113862230B (zh) * 2021-09-30 2023-08-08 中牧实业股份有限公司 一种猪伪狂犬病病毒基因缺失株、疫苗组合物及其制备方法和应用

Family Cites Families (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE148705C (hu)
US3137631A (en) 1959-12-01 1964-06-16 Faberge Inc Encapsulation in natural products
US3080291A (en) 1960-06-10 1963-03-05 Jensen Salsberg Lab Inc Serial passage of distemper virus in tissue cultures of chick embryo and canine tissue and vaccine therefrom
US3959457A (en) 1970-06-05 1976-05-25 Temple University Microparticulate material and method of making such material
US4015100A (en) 1974-01-07 1977-03-29 Avco Everett Research Laboratory, Inc. Surface modification
US4122167A (en) 1977-02-09 1978-10-24 Merck & Co., Inc. Respiratory synctial vaccine
US4205060A (en) 1978-12-20 1980-05-27 Pennwalt Corporation Microcapsules containing medicament-polymer salt having a water-insoluble polymer sheath, their production and their use
US4224412A (en) 1979-05-01 1980-09-23 Dorofeev Viktor M Living virus culture vaccine against canine distemper and method of preparing same
US4554159A (en) 1981-11-12 1985-11-19 Institute Merieux Vaccine and method of immunizing against herpes simplex virus (types 1 and 2)
US4452747A (en) 1982-03-22 1984-06-05 Klaus Gersonde Method of and arrangement for producing lipid vesicles
GB8319302D0 (en) 1983-07-16 1983-08-17 Tpt Ltd Container
US4468346A (en) 1983-10-27 1984-08-28 The United States Of America As Represented By The Secretary Of Agriculture Monoclonal antibodies to porcine immunoglobulins
DE3405100A1 (de) 1984-02-14 1985-08-14 Drägerwerk AG, 2400 Lübeck Pt-katalysator auf einem traeger als luftreinigungsmittel
US4744933A (en) 1984-02-15 1988-05-17 Massachusetts Institute Of Technology Process for encapsulation and encapsulated active material system
US5008050A (en) 1984-06-20 1991-04-16 The Liposome Company, Inc. Extrusion technique for producing unilamellar vesicles
US4921706A (en) 1984-11-20 1990-05-01 Massachusetts Institute Of Technology Unilamellar lipid vesicles and method for their formation
US4606940A (en) 1984-12-21 1986-08-19 The Ohio State University Research Foundation Small particle formation and encapsulation
US5206163A (en) 1985-07-08 1993-04-27 Chiron Corporation DNA encoding bovine diarrhea virus protein
ZA864879B (en) 1985-07-08 1987-03-25 Wallone Region Vaccines and diagnostics derived from boving diarrhoea virus
US4753884A (en) 1986-01-28 1988-06-28 Novagene, Inc. Pseudorabies virus mutants, vaccines containing same, methods for the production of same and methods for the use of same
JPS62198626A (ja) 1986-02-26 1987-09-02 Biseibutsu Kagaku Kenkyusho:Kk 血球凝集性脳脊髄炎ウイルス感染症予防ワクチン
FR2602791B1 (fr) 1986-08-18 1988-11-10 Ministere Agri Direction Quali Procede de culture du virus de la rhinotracheite infectieuse de la dinde, et vaccin prepare a partir du virus ainsi obtenu
NZ222465A (en) 1986-11-07 1992-11-25 Pasteur Institut Nanb (non a, non b hepatitis viral) antigen
US5009956A (en) 1987-02-24 1991-04-23 Univ Minnesota Phospholipase A2-resistant liposomes
DE3833925A1 (de) 1988-03-11 1989-09-21 Inst Angewandte Biotechnologie Verfahren und herstellung von virus und viralem antigen und vorrichtung hierzu
US5213759A (en) 1988-05-05 1993-05-25 Elopak Systems A.G. Sterilization
US4927637A (en) 1989-01-17 1990-05-22 Liposome Technology, Inc. Liposome extrusion method
US4944948A (en) 1989-02-24 1990-07-31 Liposome Technology, Inc. EGF/Liposome gel composition and method
US5132117A (en) 1990-01-11 1992-07-21 Temple University Aqueous core microcapsules and method for their preparation
AU7007491A (en) 1990-02-02 1991-08-08 Schweiz. Serum- & Impfinstitut Bern Cdna corresponding to the genome of negative-strand rna viruses, and process for the production of infectious negative-strand rna viruses
CA2290906C (en) 1991-06-06 2003-04-01 Stichting Centraal Diergeneeskundig Instituut Causative agent of the mystery swine disease, vaccine compositions and diagnostic kits
US5846805A (en) 1991-08-26 1998-12-08 Boehringer Ingelheim Animal Health, Inc. Culture of swine infertility and respiratory syndrome virus in simian cells
US6042830A (en) 1992-08-05 2000-03-28 Boehringer Ingelheim Vetmedica, Inc. Viral agent associated with mystery swine disease
DE69214657T4 (de) 1991-08-26 2003-07-17 Boehringer Ingelheim Vetmed Vakzine gegen und diagnosemethode für das schweine-unfruchtbarkeits- und atmungs-syndrom (suas)
US6080570A (en) 1991-08-26 2000-06-27 Boehringer Ingelheim Vetmedica, Inc. Method of producing a vaccine for Swine Infertility and Respiratory Syndrome
US6982160B2 (en) 1991-08-26 2006-01-03 Boehringer Ingelheim Vetmedica, Inc. Immunogenic compositions that include SIRS virus
MX9204885A (es) 1991-08-26 1994-05-31 Boehringer Animal Health Inc Composicion de vacuna que comprende virus del sindrome de infertilidad y respiratorio de los cerdos.
WO1993006211A1 (en) 1991-09-16 1993-04-01 Collins James E Vaccine for mystery swine disease and method for diagnosis thereof
CA2121241C (en) 1991-10-14 2007-12-04 Nicolaas Visser Porcine reproductive respiratory syndrome vaccine and diagnostic
FR2686097B1 (fr) 1992-01-14 1994-12-30 Rhone Merieux Preparation d'antigenes et de vaccins de virus de la mystery disease, antigenes et vaccins obtenus pour la prevention de cette maladie.
US5338543A (en) 1992-02-27 1994-08-16 Ambico, Inc. Thimerosal inactivated mycoplasma hyopneumoniae vaccine
TW289731B (hu) 1992-07-09 1996-11-01 Akzo Nv
US5695766A (en) 1992-10-30 1997-12-09 Iowa State University Research Foundation Highly virulent porcine reproductive and respiratory syndrome viruses which produce lesions in pigs and vaccines that protect pigs against said syndrome
US6592873B1 (en) 1992-10-30 2003-07-15 Iowa State University Research Foundation, Inc. Polynucleic acids isolated from a porcine reproductive and respiratory syndrome virus (PRRSV) and proteins encoded by the polynucleic acids
US6773908B1 (en) 1992-10-30 2004-08-10 Iowa State University Research Foundation, Inc. Proteins encoded by polynucleic acids of porcine reproductive and respiratory syndrome virus (PRRSV)
US6380376B1 (en) 1992-10-30 2002-04-30 Iowa State University Research Foundation Proteins encoded by polynucleic acids of porcine reproductive and respiratory syndrome virus (PRRSV)
US6251397B1 (en) 1992-10-30 2001-06-26 Iowa State University Research Foundation, Inc. Proteins encoded by polynucleic acids isolated from a porcine reproductive and respiratory syndrome virus and immunogenic compositions containing the same
US5419907A (en) 1992-11-10 1995-05-30 Iowa State University Research Foundation, Inc. Pathogenic porcine respiratory coronavirus
AU681874B2 (en) 1993-02-08 1997-09-11 Bayer Corporation Process for growing porcine reproductive and respiratory syndrome virus and its use in vaccines
ES2074950B1 (es) 1993-09-17 1996-03-16 Iberica Cyanamid Vacuna para la prevencion de la enfermedad reproductiva y respiratoria de la cerda.
EP0659885A1 (en) 1993-12-21 1995-06-28 Akzo Nobel N.V. Vaccine against viruses associated with antibody-dependent-enhancement of viral infectivity
DE4407489A1 (de) 1994-03-07 1995-09-14 Bayer Ag Vakzine zur Prävention von Respirations- und Reproduktionserkrankungen des Schweines
ATE206455T1 (de) 1994-04-11 2001-10-15 Akzo Nobel Nv Europäische vakzinstämme des fortplanzungs- atmungs-syndromsvirus des schweins
DE69530227T2 (de) 1994-04-15 2004-04-01 Temple University Methode zum einkapseln mittels eines wässrigen lösungsmittels und mikrokapseln
DK53595A (da) 1994-05-13 1995-11-14 Iberica Cyanamid Rekombinante PRRSV-proteiner, diagnostiske kits og vaccine indeholdende sådanne rekombinante PRRSV-proteiner
PT783321E (pt) 1994-08-05 2006-08-31 Univ Minnesota Sequencia nucleotidica viral vr-2332 e metodos de utilizacao
DE69632658T2 (de) 1995-03-14 2005-06-09 Akzo Nobel N.V. Expression in der selben Zelle von Polypeptide vom schweinen reproduktiven und respiratorischen Syndrom
US5690940A (en) 1995-06-21 1997-11-25 Regents Of The University Of Minnesota Low pathogencity PRRS live virus vaccines and methods of preparation thereof
ES2102971B1 (es) 1996-01-25 1998-03-01 Hipra Lab Sa Nueva cepa atenuada del virus causante del sindrome respiratorio y reproductivo porcino (prrs), las vacunas y medios de diagnostico obtenibles con la misma y los procedimientos para su obtencion.
US5866401A (en) 1996-03-01 1999-02-02 Schering Corporation Porcine reproductive and respiratory syndrome vaccine
US6015663A (en) 1996-03-01 2000-01-18 The United States Of America As Represented By The Secretary Of Agriculture Restriction enzyme screen for differentiating porcine reproductive and respiratory syndrome virus strains
CZ273798A3 (cs) 1996-03-01 1999-02-17 Schering Corporation Vakcína a způsob ochrany proti reprodukčnímu a respiračnímu syndromu vepřů
US5976537A (en) 1996-07-02 1999-11-02 The United States Of America As Represented By The Secretary Of Agriculture Porcine reproductive and respiratory syndrome vaccine
DE69704011T2 (de) 1996-10-09 2001-06-07 Akzo Nobel Nv Europäische Vakzinstämme des Fortplanzungs-Atmungs-Syndromsvirus des Sweins (PRRSV)
US20040224327A1 (en) 1996-10-30 2004-11-11 Meulenberg Johanna Jacoba Maria Infectious clones of RNA viruses and vaccines and diagnostic assays derived thereof
EP0839912A1 (en) 1996-10-30 1998-05-06 Instituut Voor Dierhouderij En Diergezondheid (Id-Dlo) Infectious clones of RNA viruses and vaccines and diagnostic assays derived thereof
WO1998035023A1 (en) 1997-02-07 1998-08-13 Origen, Inc. Method for growing porcine reproductive and respiratory syndrome virus for use as vaccines and diagnostic assays
PT980387E (pt) 1997-05-06 2007-07-31 Boehringer Ingelheim Vetmed Sítios antigénicos de prrsv que identificam sequências peptídicas do vírus prrsv para utilização em vacinas ou em ensaios de diagnóstico
US6140486A (en) 1997-06-04 2000-10-31 Calgene Llc Production of polyunsaturated fatty acids by expression of polyketide-like synthesis genes in plants
WO1998055626A2 (en) 1997-06-05 1998-12-10 Origen, Inc. Recombinant porcine reproductive and respiratory syndrome virus (prrsv) for use as a vaccine
US7211379B2 (en) 1997-10-03 2007-05-01 Merial Sas Prevention of myocarditis, abortion and intrauterine infection associated with porcine circovirus-2
US6391314B1 (en) 1997-10-03 2002-05-21 Merial Porcine circoviruses vaccines diagnostic reagents
US7618797B2 (en) 1998-12-22 2009-11-17 Pfizer Inc Infectious cDNA clone of North American porcine reproductive and respiratory syndrome (PRRS) virus and uses thereof
US7132106B2 (en) 1998-12-22 2006-11-07 Pfizer Inc. Infectious cDNA clone of North American porcine reproductive and respiratory syndrome (PRRS) virus and uses thereof
US7691389B2 (en) 1998-12-22 2010-04-06 Pfizer Inc Infectious cDNA clone of north american porcine reproductive and respiratory syndrome (PRRS) virus and uses thereof
NZ513289A (en) 1998-12-22 2003-04-29 Pfizer Prod Inc Infectious cDNA clone of north american procine reproductive and respiratory syndrome (PRRS) virus and uses thereof
FR2789695B1 (fr) 1999-02-11 2003-03-07 Merial Sas Vecteurs et vaccins viraux a base d'adenovirus porcins recombines et replicatifs
JP3961222B2 (ja) 1999-03-08 2007-08-22 ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー Ｐｒｒｓｖワクチン
DK2251419T3 (da) 1999-04-22 2012-07-02 Us Agriculture Porcint reproduktions- og respirations-syndrom-vaccine baseret på isolat JA-142
US20040213805A1 (en) 1999-10-12 2004-10-28 Verheije Monique Helene Deletions in arterivirus replicons
US20020012670A1 (en) 2000-01-26 2002-01-31 Knut Elbers Recombinant attenuation of porcine reproductive and respiratory syndrome (PRRSV)
WO2001059077A1 (en) * 2000-02-08 2001-08-16 Regents Of The University Of Minnesota Porcine reproductive and respiratory syndrome virus and methods of use
EP1156111A1 (en) 2000-05-19 2001-11-21 Stichting Dienst Landbouwkundig Onderzoek Chimeric arterivirus-like particles
US7018638B2 (en) 2000-12-19 2006-03-28 Wyeth Mycoplasma hyopneumoniae bacterin vaccine
MXPA03007751A (es) * 2001-03-09 2004-11-12 Boehringer Ingelheim Vetmed Cepas vivas atenuadas del virus prrs.
EP1397498A1 (en) 2001-05-21 2004-03-17 ID-Lelystad, Instituut voor Dierhouderij en Diergezondheid B.V. Delections in arterivirus replicons
US7279166B2 (en) 2001-12-12 2007-10-09 Virginia Tech Intellectual Properties, Inc. Chimeric infectious DNA clones, chimeric porcine circoviruses and uses thereof
US6841364B2 (en) 2002-01-22 2005-01-11 Protatek International, Inc. Infectious cDNA clones of porcine reproductive and respiratory syndrome virus and expression vectors thereof
ATE557082T1 (de) 2002-04-05 2012-05-15 Boehringer Ingelheim Vetmed Sequenz positionen zur anpassung bei prrsv
US7335361B2 (en) 2003-06-09 2008-02-26 Animal Technology Institute Taiwan Fusion antigen used as vaccine
US7722878B2 (en) 2004-06-17 2010-05-25 Boehringer Ingelheim Vetmedica, Inc. PRRSV subunit vaccines
CN101039693A (zh) * 2004-06-18 2007-09-19 明尼苏达大学董事会 鉴定病毒感染和疫苗接种的生物
BRPI0510928A (pt) 2004-06-18 2007-11-13 Univ Minnesota identificação de organismos viralmente infectados e vacinados
US7632636B2 (en) 2004-09-21 2009-12-15 Boehringer Ingelheim Vetmedica, Inc. Porcine reproductive and respiratory syndrome isolates and methods of use
US20060063151A1 (en) 2004-09-21 2006-03-23 Michael Roof Porcine reproductive and respiratory syndrome isolates and methods of use
EP1812573A1 (en) * 2004-11-11 2007-08-01 Pfizer Products Inc. Mutant porcine reproductive and respiratory syndrome virus
PL1833508T3 (pl) * 2004-11-19 2011-02-28 Intervet Int Bv Szczepy świńskiego wirusa zespołu rozrodczo-oddechowego i ich kompozycje
ES2343201T3 (es) 2005-01-13 2010-07-26 Boehringer Ingelheim Vetmedica Gmbh Vacunas contra el srrp.
ES2386973T3 (es) 2005-06-24 2012-09-10 Regents Of The University Of Minnesota Virus PRRS, clones infecciosos, mutantes de los mismos, y métodos de utilización
CN103641920B (zh) * 2005-11-29 2016-08-17 衣阿华州立大学研究基金公司 猪繁殖与呼吸综合征病毒(prrsv)的保护性抗原决定子的鉴定及其用途
WO2008109237A2 (en) 2007-02-13 2008-09-12 Washington State University Research Foundation Macrophage cell-lines for propagation of porcine reproductive and respiratory syndrome virus
WO2008121958A1 (en) 2007-04-02 2008-10-09 Boehringer Ingelheim Vetmedica, Inc. Use of prrsv vaccines to reduce pcv2 viremia
US20100003278A1 (en) 2008-07-03 2010-01-07 Boehringer Ingelheim Vetmedica, Inc. Immunological Compositions Effective for Lessening the Severity or Incidence of PRRSV Signs and Methods of Use Thereof
MX2011002046A (es) 2008-08-25 2011-04-21 Boehringer Ingelheim Vetmed Vacuna contra sindrome disgenesico y respiratorio porcino altamente patogeno (hp prrs).
US20100129398A1 (en) 2008-11-26 2010-05-27 Boehringer Ingelheim Vetmedica, Inc. Materials and Methods for Control of Porcine Reproductive and Respiratory Syndrome
EP2558118B1 (en) 2010-04-16 2019-06-05 Universiteit Gent Cross-protecting vaccine for porcine reproductive and respiratory syndrome virus
CN101920010A (zh) * 2010-06-29 2010-12-22 西北农林科技大学 表达prrsv免疫原基因的重组减毒鼠伤寒沙门氏菌载体疫苗及其制备方法
US8728487B2 (en) 2011-01-20 2014-05-20 Hua Wu Attenuated live vaccine for prevention of porcine reproductive and respiratory syndrome
MY161198A (en) 2011-02-17 2017-04-14 Boehringer Ingelheim Vetmedica Gmbh Novel european prrsv strain
UA112860C2 (uk) * 2011-02-17 2016-11-10 Бьорінгер Інгельхайм Ветмедіка Гмбх Спосіб одержання prrsv у комерційному масштабі
EP2737058A1 (en) 2011-07-29 2014-06-04 Boehringer Ingelheim Vetmedica GmbH INFECTIOUS cDNA CLONE OF EUROPEAN PRRS VIRUS AND USES THEREOF
WO2014150822A2 (en) 2013-03-15 2014-09-25 Boehringer Ingelheim Vetmedica, Inc. Porcine reproductive and respiratory syndrome virus, compositions, vaccine and methods of use
CA2930042C (en) 2013-12-20 2022-06-21 Boehringer Ingelheim Vetmedica Gmbh Prrs virus variant, european prrs virus cdna clone, and uses thereof

Also Published As

Publication number Publication date
US9534207B2 (en) 2017-01-03
AR085272A1 (es) 2013-09-18
EA201692359A1 (ru) 2017-04-28
BR112013021076B1 (pt) 2022-11-29
AU2016204983A1 (en) 2016-08-04
HRP20151031T1 (hr) 2015-11-06
MX2013009485A (es) 2014-07-09
DK2959916T3 (en) 2018-10-29
EP2959916B1 (en) 2018-08-08
US20120213810A1 (en) 2012-08-23
MX345188B (es) 2017-01-20
WO2012110489A3 (en) 2012-10-11
MX355058B (es) 2018-04-04
PT2959916T (pt) 2018-11-19
SG192820A1 (en) 2013-09-30
EA035624B1 (ru) 2020-07-16
US20190134180A1 (en) 2019-05-09
ES2692809T3 (es) 2018-12-05
BR112013021076A2 (pt) 2020-12-15
CL2013002379A1 (es) 2014-02-14
JP2014507151A (ja) 2014-03-27
ME02271B (me) 2016-02-20
ES2550258T3 (es) 2015-11-05
US20170065709A1 (en) 2017-03-09
TWI673362B (zh) 2019-10-01
CN103370078B (zh) 2016-08-10
KR102183276B1 (ko) 2020-11-26
AR117530A2 (es) 2021-08-11
EP2675475B1 (en) 2015-07-01
CA2826341C (en) 2022-02-22
CN106110318A (zh) 2016-11-16
EA038012B1 (ru) 2021-06-23
CY1116835T1 (el) 2017-03-15
UA112768C2 (uk) 2016-10-25
US20140255442A1 (en) 2014-09-11
TW201638333A (zh) 2016-11-01
EA201300915A1 (ru) 2014-02-28
MY161198A (en) 2017-04-14
CO6791570A2 (es) 2013-11-14
AU2016204983B2 (en) 2018-02-15
KR102073075B1 (ko) 2020-02-26
AU2012217169A1 (en) 2013-07-18
US10668144B2 (en) 2020-06-02
EP2959916A1 (en) 2015-12-30
UA117272C2 (uk) 2018-07-10
CA2826341A1 (en) 2012-08-23
KR20140006040A (ko) 2014-01-15
PL2959916T3 (pl) 2019-05-31
US10039821B2 (en) 2018-08-07
DK2675475T3 (en) 2015-09-14
BR122021013826B1 (pt) 2022-11-22
EP2675475A2 (en) 2013-12-25
PH12017500962A1 (en) 2017-11-20
PT2675475E (pt) 2015-10-22
SI2675475T1 (sl) 2015-10-30
WO2012110489A2 (en) 2012-08-23
KR20200015800A (ko) 2020-02-12
MY186535A (en) 2021-07-26
JP5788027B2 (ja) 2015-09-30
SMT201500236B (it) 2015-10-30
PL2675475T3 (pl) 2015-12-31
CN103370078A (zh) 2013-10-23
US8765142B2 (en) 2014-07-01
AU2012217169B2 (en) 2016-08-11
TW201300538A (zh) 2013-01-01
TWI665303B (zh) 2019-07-11
RS54231B1 (en) 2015-12-31

Similar Documents

Publication Publication Date Title
US10668144B2 (en) European PRRSV strain
US7368117B2 (en) PRRS vaccines
US20110117129A1 (en) Vaccine Against Highly Pathogenic Porcine Reproductive and Respiratory Syndrome (HP PRRS)
US9687543B2 (en) Porcine reproductive and respiratory syndrome virus compositions and uses thereof